Stock GSS GENETIC SIGNATURES LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Genetic Signatures Limited

Equities

GSS

AU000000GSS4

Market Closed - Australian S.E.
Other stock markets
 02:10:43 2024-05-01 am EDT 		5-day change 1st Jan Change
0.7 AUD +0.72% Intraday chart for Genetic Signatures Limited +2.94% +60.92%
Apr. 30 Genetic Signatures Appoints Interim CEO MT
Apr. 28 Genetic Signatures' Sales Drop in Fiscal Q3 MT

Summary

  • From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

  • The prospective high growth for the next fiscal years is among the main assets of the company
  • The company is in a robust financial situation considering its net cash and margin position.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • Analyst opinion has improved significantly over the past four months.
  • Over the past twelve months, analysts' opinions have been strongly revised upwards.

Weaknesses

  • The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
  • The company has insufficient levels of profitability.
  • The company's "enterprise value to sales" ratio is among the highest in the world.
  • The company appears highly valued given the size of its balance sheet.
  • For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
  • The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
  • For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
  • For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
  • The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.

Ratings chart - Surperformance

Sector: Advanced Medical Equipment & Technology

1st Jan change Capi. Investor Rating ESG Refinitiv
GENETIC SIGNATURES LIMITED Stock Genetic Signatures Limited
+60.92% 84.17M -
THERMO FISHER SCIENTIFIC Stock Thermo Fisher Scientific
+7.90% 217B
B
DANAHER CORPORATION Stock Danaher Corporation
+6.19% 183B
B-
INTUITIVE SURGICAL, INC. Stock Intuitive Surgical, Inc.
+10.67% 131B
B-
BOSTON SCIENTIFIC CORPORATION Stock Boston Scientific Corporation
+24.70% 106B
A-
SIEMENS HEALTHINEERS AG Stock Siemens Healthineers AG
-0.95% 62.16B
A-
EDWARDS LIFESCIENCES CORPORATION Stock Edwards Lifesciences Corporation
+10.57% 51.02B
B+
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD. Stock Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
+4.81% 50.89B
B+
AGILENT TECHNOLOGIES, INC. Stock Agilent Technologies, Inc.
-0.63% 40.16B
A
GE HEALTHCARE TECHNOLOGIES INC. Stock GE HealthCare Technologies Inc.
+1.19% 34.79B -
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
-
EV / Sales
Price to Book
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. GSS Stock
  4. Ratings Genetic Signatures Limited